JP2018535992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535992A5 JP2018535992A5 JP2018528338A JP2018528338A JP2018535992A5 JP 2018535992 A5 JP2018535992 A5 JP 2018535992A5 JP 2018528338 A JP2018528338 A JP 2018528338A JP 2018528338 A JP2018528338 A JP 2018528338A JP 2018535992 A5 JP2018535992 A5 JP 2018535992A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- lymphoma
- compound
- quinazolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 14
- 229960004528 Vincristine Drugs 0.000 claims description 10
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 10
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 9
- 229960004618 prednisone Drugs 0.000 claims description 9
- 108010001645 Rituximab Proteins 0.000 claims description 5
- 229960004641 rituximab Drugs 0.000 claims description 5
- -1 3- (5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl) -piperidine-2,6-dione hydrate Chemical compound 0.000 claims description 4
- 229960004630 Chlorambucil Drugs 0.000 claims description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 3
- 229960000684 Cytarabine Drugs 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- 229960003957 Dexamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960003048 Vinblastine Drugs 0.000 claims description 3
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 229960002436 cladribine Drugs 0.000 claims description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims description 3
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims description 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N Bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 2
- 229960001561 Bleomycin Drugs 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
- 229960004562 Carboplatin Drugs 0.000 claims description 2
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 2
- 101700084039 EPO Proteins 0.000 claims description 2
- 101710042422 EPX Proteins 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 102100008763 IFNA2 Human genes 0.000 claims description 2
- 229960001101 Ifosfamide Drugs 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 2
- 229940065638 Intron A Drugs 0.000 claims description 2
- 102100001056 KITLG Human genes 0.000 claims description 2
- 101710028765 KITLG Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 2
- 229960004961 Mechlorethamine Drugs 0.000 claims description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002450 Ofatumumab Drugs 0.000 claims description 2
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 claims description 2
- 229960002340 Pentostatin Drugs 0.000 claims description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 2
- 102100002607 TIMP1 Human genes 0.000 claims description 2
- 101700040544 TIMP1 Proteins 0.000 claims description 2
- 229960000237 Vorinostat Drugs 0.000 claims description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 2
- 229960002707 bendamustine Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 229960001467 bortezomib Drugs 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 229960004942 lenalidomide Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960003347 obinutuzumab Drugs 0.000 claims description 2
- 108010045555 obinutuzumab Proteins 0.000 claims description 2
- 229960000435 oblimersen Drugs 0.000 claims description 2
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 claims description 2
- 108010052070 ofatumumab Proteins 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960003452 romidepsin Drugs 0.000 claims description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 2
- 108010091666 romidepsin Proteins 0.000 claims description 2
- 229960005267 tositumomab Drugs 0.000 claims description 2
- 108091021661 tositumomab I-131 Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 206010025310 Other lymphomas Diseases 0.000 claims 5
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 claims 4
- 230000001351 cycling Effects 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 2
- 231100000486 side effect Toxicity 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 1
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 1
- 208000004235 Neutropenia Diseases 0.000 claims 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 1
- 230000002730 additional Effects 0.000 claims 1
- 229960002923 denileukin diftitox Drugs 0.000 claims 1
- 108010017271 denileukin diftitox Proteins 0.000 claims 1
- 210000001102 germinal center B cell Anatomy 0.000 claims 1
- 229960001507 ibrutinib Drugs 0.000 claims 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 14
- 229960004397 Cyclophosphamide Drugs 0.000 description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 229960002918 Doxorubicin Hydrochloride Drugs 0.000 description 5
- 229960005420 Etoposide Drugs 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 229960004679 Doxorubicin Drugs 0.000 description 3
- XDDAORKBJWWYJS-UHFFFAOYSA-O Glyphosate Chemical compound OC(=O)C[NH2+]CP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-O 0.000 description 2
- 239000005562 Glyphosate Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 229960001586 Procarbazine Hydrochloride Drugs 0.000 description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 2
- 229960001099 Trimetrexate Drugs 0.000 description 2
- 229940097068 glyphosate Drugs 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- DERJYEZSLHIUKF-UHFFFAOYSA-N procarbazine hydrochloride Chemical compound Cl.CNNCC1=CC=C(C(=O)NC(C)C)C=C1 DERJYEZSLHIUKF-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- AKJHMTWEGVYYSE-FXILSDISSA-N (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide Chemical compound C=1C=C(O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-FXILSDISSA-N 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- RPEPXOHTYVXVMA-CIUDSAMLSA-N (2S)-2-amino-5-[[(2S)-1-[[(1S)-1-carboxy-4-(3H-diazirin-3-yl)-4-oxobutyl]amino]-5-(3H-diazirin-3-yl)-1,5-dioxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](CCC(=O)C1N=N1)C(O)=O)CC(=O)C1N=N1 RPEPXOHTYVXVMA-CIUDSAMLSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 1
- SWXOGPJRIDTIRL-HFQRKYADSA-N (4R,7S,10S,13S,16S,19R)-10-(4-aminobutyl)-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-HFQRKYADSA-N 0.000 description 1
- DLWOTOMWYCRPLK-UVTDQMKNSA-N (4Z)-5-amino-6-(7-amino-6-methoxy-5,8-dioxoquinolin-2-yl)-4-(4,5-dimethoxy-6-oxocyclohexa-2,4-dien-1-ylidene)-3-methyl-1H-pyridine-2-carboxylic acid Chemical compound C1=CC(OC)=C(OC)C(=O)\C1=C\1C(N)=C(C=2N=C3C(=O)C(N)=C(OC)C(=O)C3=CC=2)NC(C(O)=O)=C/1C DLWOTOMWYCRPLK-UVTDQMKNSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- OJRZEKJECRTBPJ-NGAMADIESA-N (Z,5S)-5-acetamido-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate Chemical compound CC(=O)N[C@H](C(O)=O)CC\C([O-])=C\[N+]#N OJRZEKJECRTBPJ-NGAMADIESA-N 0.000 description 1
- VKDGNNYJFSHYKD-UHFFFAOYSA-N 2,5-diamino-2-(difluoromethyl)pentanoic acid;hydron;chloride Chemical compound Cl.NCCCC(N)(C(F)F)C(O)=O VKDGNNYJFSHYKD-UHFFFAOYSA-N 0.000 description 1
- NJWBUDCAWGTQAS-UHFFFAOYSA-N 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 NJWBUDCAWGTQAS-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-N,N-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- GTJXPMSTODOYNP-BTKVJIOYSA-N 3-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 GTJXPMSTODOYNP-BTKVJIOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-ARQDHWQXSA-N 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- QAWIHIJWNYOLBE-OKKQSCSOSA-N ACIVICIN Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 1
- 229950008427 ACIVICIN Drugs 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 229940028652 Abraxane Drugs 0.000 description 1
- 229960004176 Aclarubicin Drugs 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- 229950004295 Azotomycin Drugs 0.000 description 1
- 229950005567 BENZODEPA Drugs 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N Batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 Batimastat Drugs 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960003109 Daunorubicin Hydrochloride Drugs 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 229950004203 Droloxifene Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N Drostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950005133 Duazomycin Drugs 0.000 description 1
- 101700059448 EFHD1 Proteins 0.000 description 1
- 229960002046 Eflornithine Hydrochloride Drugs 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N Elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 Elsamitrucin Drugs 0.000 description 1
- 229950010625 Enloplatin Drugs 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N Etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- 229950011548 FADROZOLE Drugs 0.000 description 1
- 229950005096 FAZARABINE Drugs 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 Floxuridine Drugs 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- UXTSQCOOUJTIAC-UHFFFAOYSA-N Fosquidone Chemical compound C=1N2CC3=CC=CC=C3C(C)C2=C(C(C2=CC=C3)=O)C=1C(=O)C2=C3OP(O)(=O)OCC1=CC=CC=C1 UXTSQCOOUJTIAC-UHFFFAOYSA-N 0.000 description 1
- 229950005611 Fosquidone Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229940089022 Leuprolide Acetate Drugs 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 229960003951 Masoprocol Drugs 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N Masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 229960003058 Methotrexate Sodium Drugs 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N Methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- DRCJGCOYHLTVNR-ZUIZSQJWSA-N Mitindomide Chemical compound C1=C[C@@H]2[C@@H]3[C@H]4C(=O)NC(=O)[C@H]4[C@@H]3[C@H]1[C@@H]1C(=O)NC(=O)[C@H]21 DRCJGCOYHLTVNR-ZUIZSQJWSA-N 0.000 description 1
- 229950001314 Mitindomide Drugs 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- HRXVDDOKERXBEY-UHFFFAOYSA-N N-[bis(aziridin-1-yl)phosphoryl]-N-ethyl-1,3,4-thiadiazol-2-amine Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 1
- XJXLRNPVSQADMZ-UHFFFAOYSA-N N-methyl-N-[4-[(7-methyl-3H-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]acetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=CC(C)=NC2=CC=C(NC=N3)C3=C12 XJXLRNPVSQADMZ-UHFFFAOYSA-N 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N Nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N Neocarzinostatin Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- 229950010131 PUROMYCIN Drugs 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 229960003171 Plicamycin Drugs 0.000 description 1
- 229960004293 Porfimer Sodium Drugs 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- XKLZIVIOZDNKEQ-CLQLPEFOSA-N Sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
- 229950009641 Sparsomycin Drugs 0.000 description 1
- 229950006315 Spirogermanium Drugs 0.000 description 1
- 229950006050 Spiromustine Drugs 0.000 description 1
- 229950004330 Spiroplatin Drugs 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229950002687 Talisomycin Drugs 0.000 description 1
- 229940063683 Taxotere Drugs 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N Tiazofurin Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N Tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- 229950002376 Tirapazamine Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960004167 Toremifene Citrate Drugs 0.000 description 1
- 229950003873 Triciribine Drugs 0.000 description 1
- 229960004824 Triptorelin Drugs 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N Verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229960003895 Verteporfin Drugs 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N Vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960005212 Vindesine Sulfate Drugs 0.000 description 1
- 229960002166 Vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N VinorelbineTartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- MMRCWWRFYLZGAE-UHFFFAOYSA-N Vinzolidine Chemical compound C1C(CC)(O)CC(C2)CN1CCC(C1=CC=CC=C1N1)=C1C2(C(=O)OC)C(C(=C1)OC)=CC2=C1N(C)C1C2(C23)CCN3CC=CC2(CC)C(OC(C)=O)C11OC(=O)N(CCCl)C1=O MMRCWWRFYLZGAE-UHFFFAOYSA-N 0.000 description 1
- 229950005839 Vinzolidine Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N Vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N Zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- VUPBDWQPEOWRQP-YDYCAPBPSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R)-3-[[5-[[1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino Chemical compound O([C@H]1[C@@H]([C@H](O)[C@H](N)[C@H](C)O1)O)C(C(O)C=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCC(N)CC(=O)NCCCNCCCCN)NC(=O)C(C(O)C)NC(=O)CC(O)C(C)NC(=O)C([C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C VUPBDWQPEOWRQP-YDYCAPBPSA-N 0.000 description 1
- XASGSSXPZXRXFL-UHFFFAOYSA-L [1-(aminomethyl)cyclohexyl]methanamine;platinum(2+);sulfate Chemical compound [Pt+2].[O-]S([O-])(=O)=O.NCC1(CN)CCCCC1 XASGSSXPZXRXFL-UHFFFAOYSA-L 0.000 description 1
- ASQRQYODAQUVBR-UHFFFAOYSA-L [4-(aminomethyl)oxan-4-yl]methanamine;cyclobutane-1,1-dicarboxylate;platinum(2+) Chemical compound [Pt+2].NCC1(CN)CCOCC1.[O-]C(=O)C1(C([O-])=O)CCC1 ASQRQYODAQUVBR-UHFFFAOYSA-L 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl N-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- SVJSWELRJWVPQD-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C1NC=2NC(N)=NC(=O)C=2CC1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 SVJSWELRJWVPQD-UHFFFAOYSA-L 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940017743 dromostanolone propionate Drugs 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N ethyl N-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-M lysinate Chemical compound NCCCCC(N)C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-M 0.000 description 1
- DASQOOZCTWOQPA-GXKRWWSZSA-L methotrexate disodium Chemical compound [Na+].[Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 DASQOOZCTWOQPA-GXKRWWSZSA-L 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 238000002660 stem cell treatment Methods 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- 229960002730 vapreotide Drugs 0.000 description 1
- COFJBSXICYYSKG-FJFFLIEUSA-N vindesine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 COFJBSXICYYSKG-FJFFLIEUSA-N 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Description
æããå€ã®äŸãšããŠãéå®ãããªããïŒã¢ãã©ããµã³ïŒïœïœïœ
âïŒïŒïŒã¢ã·ãã·ã³ïŒã¢ã¯ã©ã«ãã·ã³ïŒå¡©é
žã¢ã³ããŸãŒã«ïŒã¢ã¯ããã³ïŒã¢ãã»ã¬ã·ã³ïŒã¢ã«ãã¹ãã€ãã³ïŒã¢ã«ãã¬ã¿ãã³ïŒã¢ã³ããã€ã·ã³ïŒé
¢é
žã¢ã¡ã¿ã³ããã³ïŒã¢ã ã«ãã·ã³ïŒã¢ã ãµã¯ãªã³ïŒã¢ãã¹ãããŸãŒã«ïŒã¢ã³ãã©ãã€ã·ã³ïŒã¢ã¹ãã©ã®ããŒãŒïŒã¢ã¹ãã«ãªã³ïŒã¢ã¶ã·ããžã³ïŒã¢ãŒããïŒã¢ãŸããã€ã·ã³ïŒãããã¹ã¿ããïŒãã³ãŸããïŒãã«ã«ã¿ããïŒå¡©é
žããµã³ãã¬ã³ïŒãžã¡ã·ã«é
žãã¹ããã£ãïŒããŒã¬ã·ã³ïŒç¡«é
žãã¬ãªãã€ã·ã³ïŒãã¬ãããŒã«ãããªãŠã ïŒããããªãã³ïŒãã¹ã«ãã¡ã³ïŒã«ã¯ãããã€ã·ã³ïŒã«ã«ã¹ããã³ïŒã«ã©ã»ããïŒã«ã«ããããŒïŒã«ã«ããã©ãã³ïŒã«ã«ã ã¹ãã³ïŒå¡©é
žã«ã«ãã·ã³ïŒã«ã«ãŒã¬ã·ã³ïŒã»ããã£ã³ãŽãŒã«ïŒã»ã¬ã³ãã·ãïŒïŒ£ïŒ¯ïŒžâïŒé»å®³å€ïŒïŒã¯ãã©ã ãã·ã«ïŒã·ãã¬ãã€ã·ã³ïŒã·ã¹ãã©ãã³ïŒã¯ã©ããªãã³ïŒã¡ã·ã«é
žã¯ãªã¹ãããŒã«ïŒã·ã¯ããã¹ãã¡ããïŒã·ã¿ã©ãã³ïŒãã«ã«ããžã³ïŒãã¯ãããã€ã·ã³ïŒå¡©é
žããŠãã«ãã·ã³ïŒãã·ã¿ãã³ïŒãããœã«ããã©ãã³ïŒãã¶ã°ã¢ãã³ïŒã¡ã·ã«é
žãã¶ã°ã¢ãã³ïŒãžã¢ãžã³ã³ïŒãã»ã¿ãã»ã«ïŒãããœã«ãã·ã³ïŒå¡©é
žãããœã«ãã·ã³ïŒããããã·ãã§ã³ïŒã¯ãšã³é
žããããã·ãã§ã³ïŒããããªã³é
žããã¢ã¹ã¿ããã³ïŒãã¥ã¢ãŸãã€ã·ã³ïŒãšããã¬ãã»ãŒãïŒå¡©é
žãšããã«ããã³ïŒãšã«ãµããã«ã·ã³ïŒãšã³ããã©ãã³ïŒãšã³ããã¡ãŒãïŒãšãããããžã³ïŒå¡©é
žãšãã«ãã·ã³ïŒãšã«ãããŸãŒã«ïŒå¡©é
žãšãœã«ãã·ã³ïŒãšã¹ãã©ã ã¹ãã³ïŒãªã³é
žãšã¹ãã©ã ã¹ãã³ãããªãŠã ïŒãšã¿ãããŸãŒã«ïŒãšããã·ãïŒãªã³é
žãšããã·ãïŒãšãããªã³ïŒå¡©é
žãã¡ãããŸãŒã«ïŒãã¡ã¶ã©ãã³ïŒãã§ã³ã¬ãããïŒããã¯ã¹ãŠãªãžã³ïŒãªã³é
žãã«ãã©ãã³ïŒãã«ãªããŠã©ã·ã«ïŒãã«ãã·ã¿ãã³ïŒãã¹ããã³ïŒãã¹ããªãšã·ã³ãããªãŠã ïŒã²ã ã·ã¿ãã³ïŒå¡©é
žã²ã ã·ã¿ãã³ïŒããŒã»ããã³ïŒããããã·å°¿çŽ ïŒå¡©é
žã€ãã«ãã·ã³ïŒã€ãã¹ãã¡ããïŒã€ã«ã¢ãã·ã³ïŒã€ãããã©ãã³ïŒã€ãªããã«ã³ïŒå¡©é
žã€ãªããã«ã³ïŒé
¢é
žã©ã³ã¬ãªããïŒã©ããããïŒã¬ãããŸãŒã«ïŒé
¢é
žãã€ãããªãïŒå¡©é
žãªã¢ããŸãŒã«ïŒãã¡ãã¬ããœãŒã«ãããªãŠã ïŒãã ã¹ãã³ïŒå¡©é
žããœããµã³ããã³ïŒããœããã³ãŒã«ïŒã¡ã€ã¿ã³ã·ã³ïŒå¡©é
žã¡ã¯ãã¬ã¿ãã³ïŒé
¢é
žã¡ã²ã¹ãããŒã«ïŒé
¢é
žã¡ã¬ã³ã²ã¹ãããŒã«ïŒã¡ã«ãã¡ã©ã³ïŒã¡ãã¬ãªã«ïŒã¡ã«ã«ããããªã³ïŒã¡ããã¬ããµãŒãïŒã¡ããã¬ããµãŒããããªãŠã ïŒã¡ãããªã³ïŒã¡ãã¬ããïŒããã³ãããïŒããã«ã«ã·ã³ïŒããã¯ããã³ïŒããã®ãªã³ïŒãããã«ã·ã³ïŒãã€ããã€ã·ã³ïŒããã¹ãã«ïŒããã¿ã³ïŒå¡©é
žããããµã³ããã³ïŒãã³ãã§ããŒã«é
žïŒãã³ããŸãŒã«ïŒãã¬ã©ãã€ã·ã³ïŒãªã«ããã©ãã³ïŒãªãã·ã¹ã©ã³ïŒãã¯ãªã¿ãã»ã«ïŒãã¬ã¹ãã«ã¬ãŒãŒïŒããªãªãã€ã·ã³ïŒãã³ã¿ã ã¹ãã³ïŒç¡«é
žããããã€ã·ã³ïŒãã«ãã¹ãã¡ããïŒãããããã³ïŒããã¹ã«ãã¡ã³ïŒå¡©é
žããããµã³ããã³ïŒããªã«ãã€ã·ã³ïŒããã¡ã¹ã¿ã³ïŒãã«ãã£ããŒãããªãŠã ïŒãã«ãã£ããã€ã·ã³ïŒãã¬ããã ã¹ãã³ïŒå¡©é
žããã«ã«ããžã³ïŒãã¥ãŒããã€ã·ã³ïŒå¡©é
žãã¥ãŒããã€ã·ã³ïŒãã©ãŸããªã³ïŒãªãããªã³ïŒããããã·ã³ïŒãµãã£ã³ãŽãŒã«ïŒå¡©é
žãµãã£ã³ãŽãŒã«ïŒã»ã ã¹ãã³ïŒã·ã ãã©ãŒã³ïŒã¹ãã«ãã»ãŒããããªãŠã ïŒã¹ãã«ãœãã€ã·ã³ïŒå¡©é
žã¹ããã²ã«ãããŠã ïŒã¹ããã ã¹ãã³ïŒã¹ãããã©ãã³ïŒå¹¹çŽ°èåŠçœ®ãäŸãã°ïŒ°ïŒ€ïŒ¡âïŒïŒïŒïŒã¹ãã¬ãããã°ãªã³ïŒã¹ãã¬ãããŸã·ã³ïŒã¹ããã§ãã«ïŒã¿ãªãœãã€ã·ã³ïŒãã³ã¬ã©ã³ãããªãŠã ïŒã¿ããœããŒã«ïŒãã¬ããŒã«ïŒå¡©é
žããããµã³ããã³ïŒãã¢ãã«ãã£ã³ïŒãããã·ãïŒãããã·ãã³ïŒãã¹ãã©ã¯ãã³ïŒãã¢ãããªã³ïŒããªã°ã¢ãã³ïŒããªããïŒãã¢ãŸããªã³ïŒãã©ãã¶ãã³ïŒã¯ãšã³é
žãã¬ããã§ã³ïŒé
¢é
žãã¬ã¹ããã³ïŒãªã³é
žããªã·ãªãã³ïŒããªã¡ãã¬ãã»ãŒãïŒã°ã«ã¯ãã³é
žããªã¡ãã¬ãã»ãŒãïŒããªããã¬ãªã³ïŒå¡©é
žããããŸãŒã«ïŒãŠã©ã·ã«ãã¹ã¿ãŒãïŒãŠã¬ããïŒããã¬ãªããïŒãã«ããã«ãã£ã³ïŒç¡«é
žãã³ãã©ã¹ãã³ïŒç¡«é
žãã³ã¯ãªã¹ãã³ïŒãã³ãã·ã³ïŒç¡«é
žãã³ãã·ã³ïŒç¡«é
žããããžã³ïŒç¡«é
žãã³ã°ãªã·ããŒãïŒç¡«é
žãã³ãã€ãã·ã³ïŒé
ç³é
žããã¬ã«ãã³ïŒç¡«é
žãã³ãã·ãžã³ïŒç¡«é
žãã³ãŸãªãžã³ïŒãããŸãŒã«ïŒãŒããã©ãã³ïŒãžãã¹ã¿ãã³ïŒåã³å¡©é
žãŸã«ãã·ã³ãæããããã
ããç¹å®ã®å®æœåœ¢æ
ã«ãããŠã第ïŒæŽ»æ§å€ã¯ããªããªã¡ã«ã»ã³ãïŒâãâããããªããã·ããããªããããºããããã·ãã¢ãããïŒïŒïŒïŒ©ãã·ãã¢ãããïŒïŒïŒ¹ã€ããªãã¢ãããïŒïŒïŒïŒ©ã€ããªãã¢ããããªãã¡ãã ããããã¬ã³ããã·ãããããã³ããã©ã©ãã³ãã·ã¯ããã¹ãã¡ãããã¯ãã©ã ãã·ã«ããã³ãã ã¹ãã³ãã«ã«ã ã¹ãã³ãã€ãã¹ãã¡ããããã¬ãããŸã³ããããµã¡ã¿ãŸã³ãã·ã¹ãã©ãã³ãã«ã«ããã©ãã³ããªããµãªãã©ãã³ããã«ãã©ãã³ããã³ãã¹ã¿ãã³ãã¯ã©ããªãã³ãã·ã¿ã©ãã³ãã²ã ã·ã¿ãã³ãã¡ããã¬ããµãŒãããã©ã©ãã¬ããµãŒãããã³ã¯ãªã¹ãã³ãç¡«é
žãã³ãã©ã¹ãã³ããããœã«ãã·ã³ãããããµã³ããã³ããšããã·ããããªãã¹ã¿ããããã«ããŸããããããã€ãã³ãžãããã¯ã¹ãã€ãã«ããããã€ãã©ãªã·ããã€ã³ããã³ïŒ¡ãçµæãã€ã³ã¿ãŒãã§ãã³ã¢ã«ãã¡âïŒïœãããããã·ã³ãã¬ããªããã€ããå¡©é
žã¡ã¯ãã¬ã¿ãã³ããã¬ãªããµãã©ã«ãããªãã¹ã¿ãããåã³ãã¬ãªãã€ã·ã³ããŸãã¯ãããã®çµã¿åããããéžæãããã
ããç¹å®ã®å®æœåœ¢æ
ã«ãããŠãååç©ïŒã¯ãã·ã¯ããã¹ãã¡ãããå¡©é
žãããœã«ãã·ã³ãç¡«é
žãã³ã¯ãªã¹ãã³ãåã³ãã¬ãããŸã³ãšçµã¿åãããŠæäžãããã
ããç¹å®ã®å®æœåœ¢æ
ã«ãããŠãååç©ïŒã¯ãã·ã¯ããã¹ãã¡ãããç¡«é
žãã³ã¯ãªã¹ãã³ãå¡©é
žããã«ã«ããžã³åã³ãã¬ãããŸã³ãšçµã¿åãããŠæäžãããã
ããç¹å®ã®å®æœåœ¢æ
ã«ãããŠãååç©ïŒã¯ãã·ã¯ããã¹ãã¡ãããç¡«é
žãã³ã¯ãªã¹ãã³åã³ãã¬ãããŸã³ãšçµã¿åãããŠæäžãããã
ããç¹å®ã®å®æœåœ¢æ
ã«ãããŠãååç©ïŒã¯ããšããã·ããã·ã¯ããã¹ãã¡ãããç¡«é
žãã³ã¯ãªã¹ãã³ãå¡©é
žãããœã«ãã·ã³åã³ãã¬ãããŸã³ãšçµã¿åãããŠæäžãããã
ããç¹å®ã®å®æœåœ¢æ
ã«ãããŠãååç©ïŒã¯ãã·ã¯ããã¹ãã¡ãããç¡«é
žãã³ã¯ãªã¹ãã³ãå¡©é
žãããœã«ãã·ã³åã³ãããµã¡ã¿ãŸã³ãšçµã¿åãããŠæäžãããã
ããç¹å®ã®å®æœåœ¢æ
ã«ãããŠãååç©ïŒã¯ããªããã·ãããã·ã¯ããã¹ãã¡ãããç¡«é
žãããœã«ãã·ã³ãå¡©é
žãã³ã¯ãªã¹ãã³ãåã³ãã¬ãããŸã³ãšçµã¿åãããŠæäžãããã
ããç¹å®ã®å®æœåœ¢æ
ã«ãããŠãååç©ïŒã¯ããªããã·ãããã·ã¯ããã¹ãã¡ãããç¡«é
žãã³ã¯ãªã¹ãã³åã³ãã¬ãããŸã³ãšçµã¿åãããŠæäžãããã
ããç¹å®ã®å®æœåœ¢æ
ã«ãããŠãååç©ïŒã¯ããªããã·ããããšããã·ãããã¬ãããŸã³ãç¡«é
žãã³ã¯ãªã¹ãã³ãã·ã¯ããã¹ãã¡ããåã³å¡©é
žãããœã«ãã·ã³ãšçµã¿åãããŠæäžãããã
Claims (24)
- ãªã³ãè «ã®åŠçœ®ãé²æ¢ã管çåã³ïŒãŸãã¯æ¹åãããããåŠçœ®ã管çãåã³ïŒãŸãã¯æ¹åã«é¢é£ããå¯äœçšãäœæžããªããè¡ãããã®å»è¬çµæç©ã§ãã£ãŠã以äžã®æ§é ïŒ
ïŒïœïŒïŒæ¥éã®æäžæéãç¶ããŠïŒæ¥éã®äŒæ¢æéïŒãŸãã¯
ïŒïœïŒïŒïŒæ¥éã®æäžæéãç¶ããŠïŒæ¥éã®äŒæ¢æé
ãå«ããµã€ã¯ãªã³ã°çæ³ã«ãããæäžã«äœ¿çšããããã®ã§ãããåèšå»è¬çµæç©ã - åèšååç©ããïŒâïŒïŒâã¢ããâïŒâã¡ãã«âïŒâãªããœâïŒïŒšâãããŸãªã³âïŒâã€ã«ïŒâãããªãžã³âïŒïŒïŒâãžãªã³ã®æº¶åªåç©ã§ãããè«æ±é ïŒã«èšèŒã®å»è¬çµæç©ã
- åèšååç©ããïŒâïŒïŒâã¢ããâïŒâã¡ãã«âïŒâãªããœâïŒïŒšâãããŸãªã³âïŒâã€ã«ïŒâãããªãžã³âïŒïŒïŒâãžãªã³ã®æ°Žåç©ã§ãããè«æ±é ïŒã«èšèŒã®å»è¬çµæç©ã
- åèšååç©ããïŒâïŒïŒâã¢ããâïŒâã¡ãã«âïŒâãªããœâïŒïŒšâãããŸãªã³âïŒâã€ã«ïŒâãããªãžã³âïŒïŒïŒâãžãªã³ã®è¬åŠçã«èš±å®¹å¯èœãªå¡©ã§ãããè«æ±é ïŒã«èšèŒã®å»è¬çµæç©ã
- åèšååç©ããïŒâïŒïŒâã¢ããâïŒâã¡ãã«âïŒâãªããœâïŒïŒšâãããŸãªã³âïŒâã€ã«ïŒâãããªãžã³âïŒïŒïŒâãžãªã³ã§ãããè«æ±é ïŒã«èšèŒã®å»è¬çµæç©ã
- åèšãµã€ã¯ãªã³ã°çæ³ããïŒæ¥éã®æäžæéãç¶ããŠïŒæ¥éã®äŒæ¢æéãå«ããè«æ±é ïŒãïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšãµã€ã¯ãªã³ã°çæ³ããïŒïŒæ¥éã®æäžæéãç¶ããŠïŒæ¥éã®äŒæ¢æéãå«ããè«æ±é ïŒãïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšå¯äœçšãã奜äžçæžå°ãå«ããè«æ±é ïŒãïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- çµå£æäžçšã®ãè«æ±é ïŒãïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšå»è¬çµæç©ããçŽïŒïœïœãçŽïŒïœïœã®çšéã§åèšååç©ãæäžããã®ã«çšãããããè«æ±é ïŒãïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšçšéããçŽïŒïœïœãŸãã¯çŽïŒïœïœã§ãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- åèšçšéããçŽïŒïœïœã§ãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- åèšçšéããçŽïŒïœïœã§ãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- åèšãµã€ã¯ãªã³ã°çæ³ããïŒãïŒåç¹°ãè¿ããããè«æ±é ïŒãïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšå»è¬çµæç©ãã第ïŒæ²»çå€ãå ±æäžããããã«çšãããããè«æ±é ïŒãïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšç¬¬ïŒæ²»çå€ãããªããªã¡ã«ã»ã³ãïŒâãâããããªããã·ããããªããããºããããã·ãã¢ãããïŒïŒïŒïŒ©ãã·ãã¢ãããïŒïŒïŒ¹ã€ããªãã¢ãããïŒïŒïŒïŒ©ã€ããªãã¢ããããªãã¡ãã ããããã¬ã³ããã·ãããããã³ããã©ã©ãã³ãã·ã¯ããã¹ãã¡ãããã¯ãã©ã ãã·ã«ããã³ãã ã¹ãã³ãã«ã«ã ã¹ãã³ãã€ãã¹ãã¡ããããã¬ãããŸã³ããããµã¡ã¿ãŸã³ãã·ã¹ãã©ãã³ãã«ã«ããã©ãã³ããªããµãªãã©ãã³ããã«ãã©ãã³ããã³ãã¹ã¿ãã³ãã¯ã©ããªãã³ãã·ã¿ã©ãã³ãã²ã ã·ã¿ãã³ãã¡ããã¬ããµãŒãããã©ã©ãã¬ããµãŒãããã³ã¯ãªã¹ãã³ãç¡«é žãã³ãã©ã¹ãã³ããããœã«ãã·ã³ãããããµã³ããã³ããšããã·ããããªãã¹ã¿ããããã«ããŸããããããã€ãã³ãžãããã¯ã¹ãã€ãã«ããããã€ãã©ãªã·ããã€ã³ããã³ïŒ¡ãçµæãã€ã³ã¿ãŒãã§ãã³ã¢ã«ãã¡âïŒïœãããããã·ã³ãã¬ããªããã€ããå¡©é žã¡ã¯ãã¬ã¿ãã³ããã¬ãªããµãã©ã«ãããªãã¹ã¿ãããåã³ãã¬ãªãã€ã·ã³ããŸãã¯ãããã®çµã¿åããããéžæããããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- åèšãªã³ãè «ããéããžãã³ãªã³ãè «ã§ãããè«æ±é ïŒãïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšãªã³ãè «ããã³ãŸãæ§å€§çŽ°èå现èãªã³ãè «ã§ãããè«æ±é ïŒãïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšã³ãŸãæ§å€§çŽ°èå现èãªã³ãè «ãã掻æ§å现èåã§ãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- åèšã³ãŸãæ§å€§çŽ°èå现èãªã³ãè «ããèèœäžå¿ïŒ¢çŽ°èåã§ãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- åèšã³ãŸãæ§å€§çŽ°èå现èãªã³ãè «ããæªåé¡ã®èµ·å§çŽ°èã®ãã®ã§ãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- åèšãªã³ãè «ãããã³ãã«çŽ°èãªã³ãè «ã§ãããè«æ±é ïŒãïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšãªã³ãè «ããåçºæ§ãŸãã¯é£æ²»æ§ã§ãããè«æ±é ïŒãïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšã³ãŸãæ§å€§çŽ°èå现èãªã³ãè «ããåçºæ§ãŸãã¯é£æ²»æ§ã§ãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562262263P | 2015-12-02 | 2015-12-02 | |
US62/262,263 | 2015-12-02 | ||
PCT/US2016/064392 WO2017096024A1 (en) | 2015-12-02 | 2016-12-01 | Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018535992A JP2018535992A (ja) | 2018-12-06 |
JP2018535992A5 true JP2018535992A5 (ja) | 2020-01-16 |
Family
ID=57614460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018528338A Pending JP2018535992A (ja) | 2015-12-02 | 2016-12-01 | ïŒâïŒïŒâã¢ããâïŒâã¡ãã«âïŒâãªããœâïŒïœâãããŸãªã³âïŒâã€ã«ïŒâãããªãžã³âïŒïŒïŒâãžãªã³ã䜿çšãããµã€ã¯ãªã³ã°çæ³ |
Country Status (13)
Country | Link |
---|---|
US (1) | US10159675B2 (ja) |
EP (1) | EP3383398A1 (ja) |
JP (1) | JP2018535992A (ja) |
KR (1) | KR20180088401A (ja) |
AU (1) | AU2016364753A1 (ja) |
BR (1) | BR112018010964A2 (ja) |
CA (1) | CA3006758A1 (ja) |
CL (1) | CL2018001434A1 (ja) |
EA (1) | EA201891289A1 (ja) |
IL (1) | IL259597A (ja) |
MX (1) | MX2018006779A (ja) |
SG (1) | SG11201804367PA (ja) |
WO (1) | WO2017096024A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10973822B2 (en) | 2015-07-02 | 2021-04-13 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
WO2018165142A1 (en) * | 2017-03-07 | 2018-09-13 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
US20220008477A1 (en) | 2018-11-08 | 2022-01-13 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | ãã£ãã¹ ã€ã³ã¯ïŒ | æäœæš¡å£ç©ããã³ä»ã®çµåã¿ã³ãã¯è³ªã®ããã®ã¿ã³ãã¯è³ªéªšæ Œ |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
GB0205395D0 (en) * | 2002-03-07 | 2002-04-24 | Univ Southampton | Materials and methods relating to the treatment of lymphoma |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
MX2007005884A (es) | 2004-11-16 | 2008-02-12 | Amgen Mountain View Inc | Andamios de proteina y usos de los mismos. |
DK2420497T3 (en) | 2006-09-26 | 2016-03-07 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
CA2829592A1 (en) * | 2011-03-11 | 2012-09-20 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
MX2013010360A (es) | 2011-03-11 | 2014-04-14 | Celgene Corp | Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos. |
WO2014004990A2 (en) * | 2012-06-29 | 2014-01-03 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
AR099385A1 (es) | 2014-01-15 | 2016-07-20 | Celgene Corp | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona |
EP3166635A1 (en) * | 2014-07-11 | 2017-05-17 | Celgene Corporation | Combination therapy for cancer |
US10973822B2 (en) | 2015-07-02 | 2021-04-13 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
EA201890585A1 (ru) | 2015-08-27 | 2018-11-30 | СелЎжОМ ÐПÑпПÑейÑÐœ | СПÑÑÐ°Ð²Ñ 3-(5-аЌОМП-2-ЌеÑОл-4-ПкÑП-4h-Ñ ÐžÐœÐ°Ð·ÐŸÐ»ÐžÐœ-3-Ол)пОпеÑОЎОМ-2,6-ЎОПМа |
-
2016
- 2016-12-01 US US15/367,117 patent/US10159675B2/en not_active Expired - Fee Related
- 2016-12-01 MX MX2018006779A patent/MX2018006779A/es unknown
- 2016-12-01 JP JP2018528338A patent/JP2018535992A/ja active Pending
- 2016-12-01 AU AU2016364753A patent/AU2016364753A1/en not_active Abandoned
- 2016-12-01 EA EA201891289A patent/EA201891289A1/ru unknown
- 2016-12-01 EP EP16819227.6A patent/EP3383398A1/en not_active Withdrawn
- 2016-12-01 CA CA3006758A patent/CA3006758A1/en not_active Abandoned
- 2016-12-01 SG SG11201804367PA patent/SG11201804367PA/en unknown
- 2016-12-01 KR KR1020187015154A patent/KR20180088401A/ko unknown
- 2016-12-01 BR BR112018010964A patent/BR112018010964A2/pt not_active IP Right Cessation
- 2016-12-01 WO PCT/US2016/064392 patent/WO2017096024A1/en active Application Filing
-
2018
- 2018-05-24 IL IL259597A patent/IL259597A/en unknown
- 2018-05-29 CL CL2018001434A patent/CL2018001434A1/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018535992A5 (ja) | ||
US9834538B2 (en) | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | |
CA2595711A1 (en) | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione | |
JP2019511565A (ja) | ãã«ã¬ãŸãŒã«ãŸãã¯ãã®ã¢ããã°ãå«ãçµæç© | |
CN109475524A (zh) | çšäºåå°äžæ§ç²ç»èåå°ççç»åç©åæ¹æ³ | |
RU2010144744A (ru) | ÐПЌпПзОÑОО О ÑпПÑÐŸÐ±Ñ ÐžÐŒÐŒÑМПÑеÑапОО | |
WO2014071280A1 (en) | Treatment of cancer with pomalidomide in a renally impaired subject | |
TW201540323A (zh) | ïŒïŒïŒïŒïŒèºåºïŒïŒïŒç²åºïŒïŒïŒåŽæ°§åºïŒïŒïœïŒå¹ååïŒïŒïŒåºïŒïŒåå¶ïŒïŒïŒïŒïŒäºé ®ä¹èª¿é ç© | |
RU2002115406A (ru) | СПеЎОМеМОе, ПблаЎаÑÑее ÑвПйÑÑваЌО вÑÑÐ²ÐŸÐ±ÐŸÐ¶ÐŽÐµÐœÐžÑ Ð³ÐŸÑЌПМа ÑПÑÑа | |
JP6707088B2 (ja) | ïŒïŒïŒ¥ïŒïŒïŒ¥ïŒâïŒâã¢ããâïŒïŒ®âãžãããã«âïŒâïŒïŒâïŒãããªãžã³âïŒâã«ã«ããã«ïŒãã§ãã«ïŒâïŒïŒšâãã³ãŸïŒ»ïœïŒœã¢ãŒãã³âïŒâã«ã«ãããµãããå«ãåºäœåœ¢æ ããã®çµæç©ãããã³ãã®äœ¿çš | |
JP2023134704A (ja) | ããã®æ²»çã§ã®äœ¿çšã®ããã®ïœïœïœïŒé»å®³å€ | |
US20180221382A1 (en) | Inhibition of mk2 in the treatment of cancer | |
JP2017508737A5 (ja) | ||
JP2016515621A (ja) | ïŒâã¢ããâïŒâïŒïŒïŒïŒâãžãªããœâãããªãžã³ïŒâã€ã«ïŒâã€ãœã€ã³ããªã³âïŒïŒïŒâãžãªã³ã䜿çšããäžæ¢ç¥çµã®çã®æ²»çåã³ç®¡çã®ããã®æ¹æ³åã³çµæç© | |
JP2016501884A5 (ja) | ||
JPWO2020210418A5 (ja) | ||
CN1711090A (zh) | çšäºæ²»çæ ¢æ§æ·å·Žç»èçœè¡ç çæ°®è¥ç±»äŒŒç©åç²ç£ºé žäŸé©¬æ¿å°Œçç»å | |
JP7245548B2 (ja) | é è¡å¹¹çŽ°è移æ€æ£è ã®åŠçœ® | |
JP2018522881A5 (ja) | ||
RU2013155476A (ru) | ÐПЌпПзОÑОО О ÑпПÑÐŸÐ±Ñ ÐžÐ·ÐŒÐµÐœÐµÐœÐžÑ ÑеМПÑОпПв xlhed | |
van Gestel et al. | Locally advanced verrucous carcinoma of the oral cavity | |
CA2742030A1 (en) | Compositions and methods for treating myelodysplastic syndrome | |
JP2018502863A (ja) | çœè¡ç ã®æ²»çã®ããã®ïŒâïŒïŒâãã«ãªãâïŒâã¡ããã·ãã§ãã«ïŒâïœâïœïŒâïŒïœâã¡ãã«ã¹ã«ãã³ã€ããã€ã«ïŒã¡ãã«ïŒœãã§ãã«ïœâïŒïŒïŒïŒïŒâããªã¢ãžã³âïŒâã¢ãã³ã®äœ¿çš | |
US20110301199A1 (en) | Compositions and methods for treating myelodysplastic syndrome | |
Tehranchi et al. | Oro-facial characteristics and the surgical correction of patients affected by beta-thalassaemia: a review of the literature and report of a case |